Business
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12
Expanded EUA includes both treatment of patients with COVID-19 and post-exposure prophylaxis (PEP) in pediatric and infant patients VANCOUVER, British
About this update from Abcellera Biologics Inc.
[{"type":"text","content":"\nExpanded EUA includes both treatment of patients with COVID-19 and post-exposure prophylaxis (PEP) in pediatric and infant patients\n\n VANCOUVER, British Columbia--(BUSINESS WIRE)--\nAbCellera (Nasdaq: ABCL) today announced the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered together to include pediatric patients under the age of 12, including neonates (infants","length":817,"tagName":"div"}]